Skip to content
Chase Therapeutics

Chase Therapeutics

Pramipexole ER (CTC-413) is a small molecule that acts as a dopamine receptor agonist and NK-1 receptor antagonist to treat motor impairment and progression in Parkinson’s disease by modulating multiple neurotransmitter pathways.

Cart 0

Your cart is currently empty.

Start Shopping